RHIZEN-PHARMACEUTICALS
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19 ”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global and Mitsui Announce 20-Year LNG Sales and Purchase Agreement12.11.2025 00:00:00 CET | Press release
Venture Global’s third long-term contract with a Japanese company6.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Mitsui & Co., Ltd. of Japan announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Mitsui will purchase 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2029. “Venture Global is honored to announce our new partnership with Mitsui, a distinguished leader in the LNG industry, to further increase the flow of U.S. LNG to Japan and the global market,” said Mike Sabel, CEO of Venture Global. “This collaboration between our two companies will strengthen energy security, enhance the balance of trade, and deepen the long-standing ties between our nations. This agreement builds upon our existing long-term relationships with Japanese companies, and we are deeply grateful for their continued trust in Venture Glob
Lattice to Showcase Advanced Industrial and Edge AI Solutions at SPS 202511.11.2025 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its participation in the upcoming SPS 2025, taking place on November 25 – 27, 2025 in Nuremberg, Germany. Lattice will deliver a presentation on secure motor control solutions and technology demonstrations with industry partners focused on advanced embedded vision and machine learning applications for the Industrial market. Who: Lattice Semiconductor What / When (GMT+2):Nov. 25 – 27, 2025: Embedded Vision and Machine Learning Demo Showcase EtherCAT Technology Group Booth (Hall 5, #310) Exor booth (Hall 9, #375) Nov. 25, 2025: Tech Talk (11 – 11:30 a.m.) Secure Connected Motion Control Platform for AC Motors: A Collaborative Innovation by Analog Devices and Lattice Semiconductor Where: Nuremberg Messe, Nuremberg, Germany SPS (Smart Product Solution) 2025 is one of the world’s leading trade fairs for industrial automation and digitalization. It showcases the entire spectrum of smart and digital autom
TOURISE Announces USD 113BN in Portfolio Investments to Accelerate the Future of Tourism11.11.2025 18:42:00 CET | Press release
High‑impact dealmaking at the inaugural TOURISE Summit catalyzes cross‑sector capital for growth across the global tourism ecosystem. TOURISE, the bold global platform shaping a new horizon for tourism, announced today that it has catalyzed investment portfolios totaling USD 113BN at the inaugural TOURISE Summit in Riyadh. The milestone reflects TOURISE’s mission to unlock high‑value deal flow by convening public and private sector leaders across tourism, technology, investment, and sustainability to set a shared roadmap for the next 50 years of global tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111666032/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE announces USD 113 BN of investment portfolios catalyzed at the inaugural TOURISE Summit. The announced portfolio investments span the full breadth of the visitor economy: luxury retail, next‑generation hotel accomm
Red Sea Global Announces the Opening of AMAALA: The World’s New Coastal Lifestyle Destination11.11.2025 16:30:00 CET | Press release
With spectacular resorts, an exclusive yacht club, and world-leading marine life institute, RSG’s latest destination sets new global standards for holistic wellness and environmental stewardship Red Sea Global (RSG), the real estate developer and pioneer of regenerative tourism, announced the highly anticipated opening of AMAALA Triple Bay during the inaugural TOURISE Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111682859/en/ Sea meets land: The world class AMAALA Triple Bay Marina Yacht Club on the Saudi Red Sea coastline Nestled across three naturally occurring bays on Saudi Arabia’s rugged north-western coast where the Hijaz Mountains meet the Red Sea, the ultra-luxury, wellness destination is set to open in the coming months. “Deriving from the Arabic word for hope, AMAALA offers a new coastal lifestyle rooted in wellness right here in Saudi Arabia. Guests and residents are invited to discover and honor what
Xsolla and Airbridge Partner to Deliver Unified Mobile and Web Performance Insights for Game Developers11.11.2025 15:36:00 CET | Press release
A New S2S Integration Connects Mobile and Web Data, Empowering Developers with a Unified View of Player Value and Marketing Performance Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Airbridge, a leading unified measurement platform for mobile marketers. This strategic partnership empowers mobile game developers with precise, cross-platform performance tracking by bridging the gap between mobile marketing efforts and purchases made through the Xsolla Web Shop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111170674/en/ (Graphic: Xsolla) As more developers turn to Web Shops to drive direct-to-consumer monetization beyond traditional app stores, understanding the full value of those off-platform transactions has become increasingly critical. With Xsolla’s new S2S integration, powered by Airbridge, deve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom